Background: Oncotype DX™ is a clinically validated, high-complexity, multianalyte reverse transcription-PCR genomic test that predicts the likelihood of breast cancer recurrence in early-stage, node-negative, estrogen receptor-positive breast cancer. The Recurrence Score™ (RS) provides a more accurate, reproducible measure of breast cancer aggressiveness and therapeutic responsiveness than standard measures. Individualized patient management requires strict performance criteria for clinical laboratory tests. We therefore investigated the analytical performance of the assay. Methods: Assays used a pooled RNA sample from fixed paraffin-embedded tissues to evaluate the analytical performance of a 21-gene panel with respect to amplification efficiency, precision, linearity, and dynamic range, as well as limits of detection and quantification. Performance variables were estimated from assays carried out with sample dilutions. In addition, individual patient samples were used to test the optimized assay for reproducibility and sources of imprecision. Results: Assay results defined acceptable operational performance ranges, including an estimated maximum deviation from linearity of <1 cycle threshold (C T ) units over a >2000-fold range of RNA concentrations, with a mean quantification bias of 0.3% and CVs of 3.2%-5.7%. An analysis of study design showed that assay imprecision
evaluated in 3 clinical-association studies to find biomarkers related to the risk of breast cancer recurrence (5) (6) (7) . Statistical analysis and modeling of these study results led to the selection of the 21 genes constituting the Oncotype DX assay panel (Table 1 ; for primers and probes for all 21 gene expression assays, see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/issue6). We chose 16 cancer-related genes for their consistent univariate association with clinical outcome in all 3 clinical association studies, and we selected 5 reference genes (ACTB, GAPDH, GUSB, RPLP0, and TFRC) 1 for their consistently low variation in expression and lack of association with clinical outcome in the same clinical studies. To compensate for sample variation in extracted RNA attributable to tissue-fixation processes, specimen age, and other variables unrelated to gene expression and patient outcome, we used the mean expression of the 5 reference genes to normalize the expression of the 16 cancer-related genes before calculating the Recurrence Score™ (RS) 2 (8 -12 ) .
samples
We defined the histopathologic characteristics of samples acceptable for Oncotype DX assay analysis during 3 preliminary clinical-association studies. Guidelines for selecting fixed paraffin-embedded tissue (FPET) samples for the Oncotype DX assay are consistent with those for selecting optimal tissue blocks for standard immunohistochemistry assays. Essentially, the block containing the greatest amount of invasive breast carcinoma that is morphologically consistent with the submitting diagnosis and having the least amount of noninvasive mammary epithelium is selected. Samples with metabolically active nontumor elements constituting Ͼ50% of the tissue have those elements dissected out before sample extraction. The goal of analytical validation was to provide an assay process with a fully optimized and documented standard operating procedure. Our studies focused on characterizing individual genes to define assay amplification efficiencies, linearity, dynamic range, reproducibility, and limits of detection and quantification. To measure the realistic limits of assay performance uncomplicated by biological variability contributed by individual samples, we created a single pooled test sample that represented a range of high and low expression values across the 21-gene panel (details in the online Data Supplement).
The final set of analytical validation studies tested the performance limits of the RS with individual patient samples to evaluate comprehensive assay performance in a way that realistically reflected patient sample testing.
fpet extraction RNA was extracted from 3 sections (10 m thick) of each FPET block. Paraffin was removed by xylene extraction followed by ethanol washing. RNA was isolated from deparaffinized tissue with the MasterPure TM Purification Kit (Epicentre Biotechnologies) with DNase I treatment, as previously described (13 ) .
rna quantification
Extracted RNA was quantitated with the RiboGreen ® fluorescence method (Molecular Probes/Invitrogen) as described previously (13 ) .
residual genomic dna
Extracts were evaluated for residual genomic DNA with a TaqMan ® quantitative PCR assay for ␤-actin DNA (13 ) . Samples exceeding the DNA threshold were retreated 1 Human genes: BAG1, BCL2-associated athanogene; BCL2, B-cell CLL/ lymphoma 2; CCNB1, cyclin B1; CD68, CD68 molecule; SCUBE2, signal peptide, CUB domain, EGF-like 2; CTSL2, cathepsin L2; ESR1, estrogen receptor 1; GRB7, growth factor receptor-bound protein 7; GSTM1, glutathione S-transferase M1; ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); MKI67, antigen identified by monoclonal antibody Ki-67; MYBL2, v-myb myeloblastosis viral oncogene homolog (avian)-like 2; PGR, progesterone receptor; AURKA, aurora kinase A; MMP11, matrix metallopeptidase 11 (stromelysin 3); BIRC5, baculoviral IAP repeat-containing 5 (survivin); ACTB, actin, beta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GUSB, glucuronidase, beta; RPLP0, ribosomal protein, large, P0; TFRC, transferrin receptor (p90, CD71). 2 Nonstandard abbreviations: RS, Recurrence Score; FPET, fixed paraffinembedded tissue; RT, reverse transcription; C T , cycle threshold. 
instrumentation and reagent calibration
We calibrated liquid-handling robots to an independent calibration system. The performance of the ABI PRISM 7900HT instruments was assessed by calculating a withinplate CV with a standardized ribonuclease P assay (Applied Biosystems).
data reference normalization and rs calculation
To make RT-PCR measurements comparable for clinical interpretation, the Oncotype DX assay normalizes gene expression measurements to the mean expression of 5 reference genes (ACTB, GAPDH, GUSB, RPLP0, and TFRC). We tested combinations of these genes for normalization performance before selecting the mean of all 5 genes for our standard reference normalization method. For each sample, normalized expression measurements are calculated as the mean cycle threshold (C T ) for the 5 reference genes minus the mean C T of triplicate measurements for each individual gene. Normalized expression measurements are scaled from 0 to 15 units, where 1 unit reflects an ϳ2-fold change in RNA quantity.
After normalization, a single quantitative RS is calculated with expression values for 16 cancer-related genes, as has been described previously (14 ) . The RS, scaled from 0 through 100, expresses the likelihood of distant breast cancer recurrence and is specific to the tumor of each individual patient.
measurement of assay amplification efficiencies
Amplification efficiency for each gene was approximated from RNA serial-dilution experiments recognizing the relationship: amplification efficiency Ϸ (2 Ϫ1/Slope Ϫ 1) ϫ 100%, where the slope is estimated from the simple linear regression of C T measurements vs log 2 RNA concentration (15, 16 ) . Each of 15 sample dilutions underwent RT-PCR analysis twice with triplicate assays. Mean C T scores from both runs were averaged to assign a final expression value for each RNA concentration measurement used in the linear regression analysis.
measurement of assay linearity
For each gene in the assay panel, the range of linear assay response was assessed by comparing the proportionality of C T values relative to the input RNA concentrations calculated for each of the 15 pooled test sample dilutions used to measure amplification efficiency (see the online Data Supplement for sample dilution details). For this analysis, the polynomial method originally proposed by Krouwer et al. (17 ) and recommended Clinical and Laboratory Standards Institute guidelines (18 ) were applied. Specifically, orthogonal polynomial regression was used to obtain coefficients and associated tests of significance for the 1st (linear), 2nd (quadratic), and 3rd (cubic) order polynomials. Given that the log of the variance in C T measurement is proportional to the mean C T , error variance was modeled by use of a log-linear variance model. Model fits were obtained by use of the PROC Mixed procedure in SAS version 8.02.
In accordance with CLSI guidelines, any degree of nonlinearity in signal response was assessed by examining the SE of the regression and selecting the higher-order (nonlinear) polynomial model with the best fit. Specifically, at each input RNA concentration, the deviation from linearity (DL) was calculated as follows:
where p(x i ) is the value of the best-fitting polynomial at RNA concentration x i . Consequently, DL i is a measure of the difference between the nonlinear model and the best-fit straight line at each of the calculated RNA concentrations.
measurement of quantitative bias and precision
Assessments of analytical bias are typically obtained by determining how much observed gene expression measurements differ from expected expression values derived from standard reference RNAs and definitive methods of analysis. Universal standard reference RNAs are not available for the 21 genes, nor are there universally accepted definitive analysis methods. Consequently, the quantitative bias and imprecision of predicted RNA concentrations relative to the calculated input RNA amounts in the series of pooled sample dilutions was estimated for each of the 21 genes. Specifically, for every C T measurement, an inverse prediction of RNA concentration was derived from the best fitting (nonlinear) polynomial calibration model derived during the linearity analysis (19 ) .
An estimate of the quantitative bias of the assay is given by the mean percent bias in prediction at each RNA concentration k (k ϭ 1 . . . 15); namely, by:
where x k is the calculated input RNA amount for the kth level and x ijk is the predicted RNA amount obtained from inverse prediction for the ith plate (i ϭ 1, 2), jth well (j ϭ 1, 2, 3), and kth RNA concentration value. As a measure of the quantitative precision of the assay, for each RNA concentration level, ANOVA was used to separate the total variability in the difference between individual predicted and calculated RNA concentrations into components of variance due to plate and well within plate, treating plates and wells within plates as random. For this purpose, a random effects model of the following form was applied to the individual differences between predicted and calculated RNA concentrations:
, where Y diff ij is the difference between the predicted and actual RNA concentrations for the ith (i ϭ 1, 2, 3) observation on the jth plate (j ϭ 1, 2), is the overall mean difference,
is the effect of the jth plate (i ϭ 1, 2), and
) is random error. We further assume that ␣s, ␤s, and s distribute independently and that the distribution of error terms vary as a function of calculated RNA concentration level (e.g., variance increases near the limit of quantification of the assay). This information was used to obtain an estimate of within-plate CV in predicted RNA concentration at the kth RNA concentration level, namely:
where x k is the calculated input RNA concentration for the kth level and 2 is the estimate of error variance derived from the ANOVA. Limit of detection and limit of quantification values were calculated for each gene as well (details in the online Data Supplement).
measurement of assay reproducibility
Reproducibility in RS and in the measurement of the expression of individual genes ensures that results remain comparable for patients over time and for different submitting pathology laboratories. Individual gene and RS reproducibility were measured by performing repeat analyses across multiple days, operators, RT-PCR plates, 7900HT instruments, and liquid-handling robots. Two operators obtained replicate C T measurements on 2 aliquots of a single RNA sample over the course of 5 days with 3 7900HT instruments and 2 liquid-handling robots. The study design has a G-efficiency of Ͼ50% (20 ) , allowing estimation of all main fixed effects, including 7900HT instrument, liquid-handling robot, and operator. All plates within days were processed in randomized order.
Mixed-effect ANOVA was used to divide calculated total variability in observed C T measurement and RS into components of variance due to days, plates within days, and within plates by treating operator, 7900HT instrument, and liquid-handling robot as fixed effects. For each of the 21 Oncotype DX genes and RS, restricted maximum likelihood estimates of the components of assay variance were obtained.
Results

amplification efficiency
Amplification efficiencies for individual genes must be similar for Oncotype DX test reference normalization and RS calculation procedures to be valid (15, 16 ) . In an optimized PCR mixture without inhibitors or reagent limitations, amplification efficiency is an inherent characteristic of the primers and probes, so under a standard set of conditions, assay sets can be directly compared for relative amplification efficiencies. Although individual patient samples may affect amplification efficiency, the influence is on all of the transcripts, leaving the relationships among the genes unaffected. Amplification efficiencies for the 16 cancer-related genes range from ϳ75% to 112%, whereas mean efficiency was ϳ88% for the reference genes (Table 2) . Some values exceeded 100% because of inherent assay error throughout the cumulative analysis of the sample-dilution series. The 95% lower confidence bounds on the amplification efficiencies reflect model error as well as inherent assay error. The results were within the experimental error expected for this study design and were consistent among all 21 gene assays.
assay linearity and dynamic range
For each gene, assay linearity was assessed by comparing the proportionality of C T measurements with respect to calculated RNA concentrations over the series of sample dilutions used to measure amplification efficiency. The quadratic and cubic polynomial terms were nonsignificant (P Ͼ0.05) for 6 genes (ACTB, BAG1, CD68, ESR1, RPLP0, and TFRC), indicating linear performance over the entire RNA range tested (2 Ϫ10 to 8 ng). Another 6 genes (CCNB1, CTSL2, GSTM1, GUSB, MKI67, and PGR) were linear over more restricted RNA concentration ranges. For the remaining genes, the deviation from the linear model was estimated to be within the prespecified acceptance criterion of 1 C T unit. Based on the prespecified CLSI criterion, each of the 21 genes in the breast cancerrecurrence gene panel had an estimated maximum deviation from linearity of 1 C T over at least an 11-log 2 (Ͼ2000-fold) concentration range (Table 3) .
At the highest RNA concentration tested in the series, 8 ng RNA/reaction, C T values for the 21 genes varied over an ϳ8-fold range (256-fold concentration range). Consequently, the lowest-expressing genes (GUSB and CTSL2) were studied over a more limited concentration range than high-expressing genes (Table 3) . Low-expressing genes in this pooled sample would be expected to demonstrate linear performances similar to highly expressed genes at higher RNA concentrations. A linear assay response was seen for all genes over the expression range typically experienced in clinical samples.
assay quantitative bias and precision
The quantitative nature of the Oncotype DX RS depends directly on analytical accuracy and precision of measurement for each component of the 21-gene assay. Analytical accuracy could not be assessed in the absence of standard reference materials for each of the 21 analytes, so quantitative bias was measured by comparing predicted RNA concentrations for each gene to expected RNA concentrations calculated for a range of sample dilutions. At every C T measurement, an inverse prediction of RNA concentration was derived from the best-fitting polynomial calibration model derived from the linearity study (19 ) . Assay bias is expressed as mean percentage deviation from the calculated value in prediction at each RNA concentration. At the 2-ng/well value used for the Oncotype DX assay, the estimated deviation from the expected value in the predicted RNA concentration ranged from Ϫ10% to 6%, with an estimated mean deviation from the expected value of Ϫ0.3% for the 16 cancer-related genes. For the reference genes, the mean percentage deviation from the expected value was 0.7%, indicating Ͼ99% mean quantitative correctness at this assay condition (Table 4) .
Each gene was analyzed for analytical imprecision of measurement. ANOVA was used at each RNA concentra- tion to estimate the total variance in predicted RNA concentration derived from the inverse calibration model vs the actual RNA concentration. This information was used to estimate the CV in the predicted RNA concentration at each known RNA concentration. For the standard reaction, the imprecision of measurement for the 16 cancer-related genes on the RNA concentration scale had a CV of 5.7%, whereas the reference genes had a CV of 3.2%. All values were well within the prespecified acceptance limit of 20% (Table 4) .
day-to-day reproducibility
SDs in C T measurements varied from ϳ0.06 to 0.15 C T units for each of the 21 genes, and the upper bounds on 2-sided 95% CIs for the CVs were all within 10%, indicating a high degree of precision and reproducibility in the assay (Table 5 ). These SD and CV values are for the estimates of total variance. The between-day SD values were close to 0 for all 21 genes. A maximum SD of 0.15 at a C T of 30 translates to a CV of 0.5%. At this level of precision it is possible to reliably distinguish a 15% change in expression for specific genes. Additionally, pairwise differences in (least-squares) mean C T values between operators, liquid-handling robots, and 7900HT instruments were calculated. The largest differences between operators, as well as between liquid-handling robots and 7900HT instruments, were Ͻ0.5 C T units for each of the 21 Oncotype DX genes (data not shown).
monitoring and controlling assay performance in the clinical reference laboratory
Clinical validation of the Oncotype DX Breast Cancer Assay was conducted after validating assay analytical performance with quality-control measures established from the results of analytical validation studies. The entire assay process, including process controls with associated performance-acceptance limits, was documented as a series of standard operating procedures that provide the basis for the current reference laboratory operation.
A standard RNA control sample is assayed at least once per batch of patient samples (Յ46 samples), and PCR controls are run in every assay plate to verify that the process and reagents continue to perform within specified ranges. RT-PCR failures, identified by analyzing the amplification curve from every assay well, are excluded from analysis. Expression values are assigned when at least 2 of 3 assay wells provide acceptable RT-PCR results. All 21 genes must have an expression value assigned for an RS to be calculated and reported.
Process monitoring in our clinical reference laboratory shows that RS reproducibility remains very high. Repeat testing with deidentified patient samples shows a cumulative SD of Ͻ2 RS units on a 100-unit scale, which represents all sources of process variation (Table 6 ).
Discussion
The Oncotype DX RS, developed to quantify likelihood of distant breast cancer recurrence for individual patients, has been clinically validated in multiple studies (14, 21, 22 ) . Each clinical study successfully met prospectively defined statistical endpoints after analytical validation studies allowed standardization of the underlying RT-PCR-based laboratory test (4, 23 ) .
This genomic diagnostic test is highly complex compared with more traditional clinical chemistry tests. Because it requires 21 quantitative measurements rather than the measurement of a single analyte, the assay does not conform to standard assay-validation formats. Nevertheless, successful analytical validation was critical to our goal of reporting quantitative results for individual patients. We defined a validation process analogous to validation methods for single analyte clinical assays to characterize assay amplification efficiency, linearity, quantification limitations, dynamic range, analytical precision, and reproducibility performance of the RT-PCR process that underlies the Oncotype DX assay for individual genes and for the assay as a whole as reflected by the RS (24 ). (25 ) . Both types test multiple analytes but diverge from one another in the quantitative analytical resolution they are able to achieve. One type of diagnostic test yields gene expression profiles for thousands or tens of thousands of candidate analytes by means of technologies such as hybridization microarrays, bead arrays, and protein mass spectrometry (26 -32 ) . Initially large analyte sets ultimately may be reduced to smaller sets that classify patients nearly as well as the original large test panel. Results obtained thus far indicate the challenge in validating this type of test for clinical utility, because such complex sets of targets-each with a relatively low precision and correctness of measurement-lend themselves to overfitting in clinical-development and -validation studies (33, 34 ) . Reproducibly measuring large panels is difficult, and such measurements typically produce high CVs. This imprecision erodes the quality of patient classifications, thereby limiting the value of these assays in clinical decision-making (35) (36) (37) .
The Oncotype DX assay is a prototype for an alternative type of genomic diagnostic test. From hundreds of candidate genes quantitatively evaluated for association with the clinical outcomes of individual patients during a series of clinical-development studies, we selected an optimal set of RT-PCR assays for high overall performance in predicting the outcome of individual patients. In contrast to tests that dichotomize patients into general populations by matching classification profiles, the output from this test is individualized; a quantitative value places a patient precisely within a defined continuum of clinical outcomes on the basis of the results of clinicalvalidation studies.
Maintaining consistent, predictable RT-PCR assay performance for individual genes throughout clinical validation allowed assay-performance effects to be reliably differentiated from true patient variability. Consequently, each biomarker was repeatedly confirmed as important in predicting patient outcome while a foundation was concurrently established for continuous monitoring of assay quality in the clinical reference laboratory setting. Because key assay-performance metrics are quantitatively monitored, patients can be assured that their clinical reports are reliable and remain consistent with clinical-validation experience. This approach to analytical validation for a high-complexity genomic diagnostic test has been demonstrated to be useful by more than 3 years of successful operation in the clinical reference laboratory setting. Routine monitoring of the ongoing performance of the test shows that it continues to perform within the originally defined analytical conditions and to give reliable results of breast cancer risk to patients and their physicians. 
